收费全文 | 1155119篇 |
免费 | 78628篇 |
国内免费 | 1726篇 |
耳鼻咽喉 | 15905篇 |
儿科学 | 31281篇 |
妇产科学 | 27964篇 |
基础医学 | 165293篇 |
口腔科学 | 33384篇 |
临床医学 | 98506篇 |
内科学 | 232360篇 |
皮肤病学 | 25253篇 |
神经病学 | 92452篇 |
特种医学 | 43580篇 |
外国民族医学 | 178篇 |
外科学 | 180060篇 |
综合类 | 18982篇 |
现状与发展 | 1篇 |
一般理论 | 298篇 |
预防医学 | 81969篇 |
眼科学 | 25791篇 |
药学 | 88522篇 |
3篇 | |
中国医学 | 2808篇 |
肿瘤学 | 70883篇 |
2021年 | 8901篇 |
2019年 | 9636篇 |
2018年 | 16094篇 |
2017年 | 11727篇 |
2016年 | 12509篇 |
2015年 | 14176篇 |
2014年 | 17429篇 |
2013年 | 26358篇 |
2012年 | 39676篇 |
2011年 | 40558篇 |
2010年 | 22449篇 |
2009年 | 20023篇 |
2008年 | 37907篇 |
2007年 | 39964篇 |
2006年 | 39566篇 |
2005年 | 38396篇 |
2004年 | 36723篇 |
2003年 | 34746篇 |
2002年 | 33729篇 |
2001年 | 60261篇 |
2000年 | 62228篇 |
1999年 | 51987篇 |
1998年 | 11598篇 |
1997年 | 10183篇 |
1996年 | 10255篇 |
1995年 | 9547篇 |
1994年 | 8817篇 |
1993年 | 8065篇 |
1992年 | 38390篇 |
1991年 | 36506篇 |
1990年 | 35249篇 |
1989年 | 34174篇 |
1988年 | 31181篇 |
1987年 | 30296篇 |
1986年 | 28221篇 |
1985年 | 26910篇 |
1984年 | 19158篇 |
1983年 | 16250篇 |
1982年 | 8419篇 |
1979年 | 16956篇 |
1978年 | 11420篇 |
1977年 | 9826篇 |
1976年 | 8492篇 |
1975年 | 9386篇 |
1974年 | 11412篇 |
1973年 | 10829篇 |
1972年 | 10273篇 |
1971年 | 9771篇 |
1970年 | 9254篇 |
1969年 | 8824篇 |
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献
Methods: Two previously published datasets (n?=?153 and n?=?641, respectively) from outpatient neuropsychological evaluations were used to test Dunham and Denney’s algorithm, and to assess concordance of failure rates with the Test of Memory Malingering and the forced choice measure of the California Verbal Learning Test, two commonly used performance validity tests.
Results: In both datasets, none of the four cutoff scores for failure on the MSVT (70%, 75%, 80%, or 85%) identified a poor validity group with proportionally aligned failure rates on other freestanding measures of performance validity. Additionally, the protocols with probable impairment did not differ from those with poor validity on cognitive measures.
Conclusions: Despite what appeared to be a promising approach to evaluating failure on the easy MSVT subtests when clinical data are unavailable (as recommended in the advanced interpretation program, or advanced interpretation [AI], of the MSVT), the current findings indicate the AI remains the gold standard for doing so. Future research should build on this effort to address shortcomings in measures of effort in neuropsychological evaluations. 相似文献